Roflumilast Foam for Seborrheic Dermatitis
Part of Skin clinical trials.
This trial tests a medicated foam called roflumilast to treat seborrheic dermatitis, a skin condition that causes redness, itching, and flaking. It may help people who have moderate to severe symptoms on their face, scalp, or body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 9 years or older.
- You must have seborrheic dermatitis for at least 3 months that has been stable for the past 4 weeks.
- Your condition must be moderate or severe, as rated by a doctor.
- The affected area can be on your scalp, face, chest, or other skin folds, but cannot cover more than 20% of your body.
- You must be in good general health, and women who can become pregnant must use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new lotion for people with mild to moderate seborrheic dermatitis (a common skin condition causing red, scaly patches on the scalp, face, or chest). The study checks safety and how well the lotion works.
This study tests whether a new foam treatment (roflumilast) can safely reduce skin rashes, itching, and other skin problems caused by checkpoint inhibitor cancer drugs. If you've developed these skin side effects from immunotherapy, this trial may help ease your symptoms.
This trial tests a new foam containing roflumilast (a medicine that reduces inflammation) for people with hidradenitis suppurativa (HS). It aims to see if the foam can safely reduce painful lumps and improve HS symptoms.
This study tests a medicated foam (Roflumilast) in children with non-segmental vitiligo to see if it can improve skin color on the face and body. It is for patients aged 2 to 17 with small patches and at least some pigmented hair in the face patches.
This study tests an oral medicine called roflumilast for adults with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective when taken by mouth, and you can join if you have not used other systemic treatments recently.
This trial tests a cream called roflumilast for people with plaque psoriasis on the body and nail psoriasis. It aims to see if the cream safely improves both skin and nails.
Hear when a new Seborrheic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.